The role of active metabolites in dihydrocodeine effects.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  International journal of clinical pharmacology and therapeutics

• Publication date

  2003-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.5414/CPP41095PMID 12665158
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of environmental and genetic factors on codeine analgesia

  2004cited by this paper
• Pharmacokinetics of intravenous and oral dihydrocodeine and its acid metabolites

  2004cited by this paper
• Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake

  2004cited by this paper
• Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine.

  2003cited by this paper
• Affinities of dihydrocodeine and its metabolites to opioid receptors.

  2002cited by this paper
• Morphine‐related metabolites differentially activate adenylyl cyclase isozymes after acute and chronic administration

  2000cited by this paper
• Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing.

  1999cited by this paper
• The detection of dihydrocodeine and its main metabolites in cases of fatal overdose

  1999cited by this paper
• Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.

  1998cited by this paper
• The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine. A cross-over study with extensive and quinidine-induced poor metabolizers.

  1998cited by this paper
• GLUCURONIDATION OF DIHYDROCODEINE BY HUMAN LIVER MICROSOMES AND THE EFFECT OF INHIBITORS

  1998cited by this paper
• Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.

  1997cited by this paper
• Analgesia by dihydrocodeine is not due to formation of dihydromorphine: evidence from nociceptive activity in rat thalamus.

  1997cited by this paper
• Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects.

  1997cited by this paper
• Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype

  1997cited by this paper
• Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects

  1996cited by this paper
• Contribution of monoaminergic modulation to the analgesic effect of tramadol.

  1996cited by this paper
• Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes.

  1995cited by this paper
• Dihydrocodeine: A new opioid substrate for the polymorphic CYP2D6 in humans

  1995cited by this paper
• Demonstration of kappa 3-opioid receptors in the SH-SY5Y human neuroblastoma cell line.

  1995cited by this paper
• Retinoic acid-induced differentiation of human neuroblastoma SH-SY5Y cells is associated with changes in the abundance of G proteins.

  1994cited by this paper
• CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone

  1993cited by this paper
• Analgesic efficacy of controlled‐release dihydrocodeine

  1991cited by this paper
• Opioid receptor-coupled second messenger systems.

  1991cited by this paper
• Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6.

  1991cited by this paper
• Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine

  1990cited by this paper
• Efficacy and tolerance of narcotic analgesics at the mu opioid receptor in differentiated human neuroblastoma cells.

  1988cited by this paper
• A human neuroblastoma cell line expresses mu and delta opioid receptor sites.

  1986cited by this paper
• Opioid receptors in human neuroblastoma SH-SY5Y cells: evidence for distinct morphine (mu) and enkephalin (delta) binding sites.

  1986cited by this paper
• Coordinate morphological and biochemical interconversion of human neuroblastoma cells.

  1983cited by this paper
• Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells.

  1981cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

  1973cited by this paper

• Characterization of Opioid Agonist Morphine Derivatives with Emphasis on Medicinal Chemistry

  2024cites this paper
• The effect of codeine administration on oxidative stress biomarkers and the expression of the neuron-specific enolase in the brain of Wistar rats

  2021cites this paper
• Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling

  2019influential citation
• Rat brain CYP2D activity alters in vivo central oxycodone metabolism, levels and resulting analgesia

  2019cites this paper
• Analgetika und Koanalgetika in der Schmerzmedizin

  2019cites this paper
• Dihydrocodeine Overdoses in a Neonate and in a 14-year-old Girl Who Were Both Genotyped as Cytochrome P450 2D6*1/*10-*36: Comparing Developmental Ages and Drug Monitoring Data With the Results of Pharmacokinetic Modeling.

  2018cites this paper
• Dihydrocodeine: safety concerns

  2016cites this paper
• Codeine and breast-feeding mothers.

  2015cites this paper
• Analgetika und Koanalgetika in der Schmerztherapie

  2015cites this paper
• Metabolism and Disposition of Prescription Opioids: A Review.

  2015cites this paper
• Analgetika und Koanalgetika in der

  2014cites this paper
• Drug Response Heterogeneity and the Genetic Variability of Cytochrome P450–Metabolizing Enzymes

  2014cites this paper
• Analgetika und Koanalgetika: Anwendung, gesetzliche Grundlagen und Probleme

  2013cites this paper
• "Citocromo P450 2D6: Variabilidade na terapêutica e na predisposição para patologias"

  2012cites this paper
• Analgesia and serum assays of controlled-release dihydrocodeine and metabolites in cancer patients with pain

  2012influential citation
• Analgesia and serum assays of controlled-release dihydrocodeine and metabolites in cancer patients with pain

  2012cites this paper
• Analgesics for Cancer Pain

  2012cites this paper
• The Role of Opioid Analgesics in the Treatment of Pain in Cancer Patients

  2012cites this paper
• Pharmacogenetics of Pain Medication

  2012cites this paper
• Role of step 2 opioid analgesics in mild-to-moderate pain intensity treatment

  2012cites this paper
• Genetics of Opioid Actions

  2011cites this paper
• CYP2D6 in the Metabolism of Opioids for Mild to Moderate Pain

  2011cites this paper
• Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active.

  2011cites this paper
• Erratum to: Pain Management in Patients with Cancer: Focus on Opioid Analgesics

  2011cites this paper
• Pain Management in Patients with Cancer: Focus on Opioid Analgesics

  2011cites this paper
• The Role of Dihydrocodeine (DHC) Metabolites in Dihydrocodeine-Related Deaths*

  2010cites this paper
• The role of dihydrocodeine (DHC) metabolites in dihydrocodeine-related deaths.

  2010cites this paper
• Personalized therapy in pain management: where do we stand?

  2010cites this paper
• Dihydrocodeine as an opioid analgesic for the treatment of moderate to severe chronic pain.

  2010cites this paper
• Applications of LC-MS/MS in forensic toxicology for the analysis of drugs and their metabolites

  2009cites this paper
• Polymorphism of human cytochrome P450 enzymes and its clinical impact

  2009cites this paper
• Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance

  2009cites this paper
• Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?

  2009cites this paper
• Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance

  2009cites this paper
• Current evidence for a modulation of low back pain by human genetic variants

  2009cites this paper
• Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers

  2009cites this paper
• Genetic modulation of the pharmacological treatment of pain.

  2009cites this paper
• Opioid pharmacology.

  2008cites this paper
• Pharmacogenetics of analgesics: toward the individualization of prescription.

  2008cites this paper
• Genetic mutations that prevent pain: implications for future pain medication.

  2008cites this paper
• PHARMACOKINETICS AND DISPOSITION Pharmacokinetic – pharmacodynamic modeling of the miotic effects of dihydrocodeine in humans

  2007influential citation
• Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication

  2007cites this paper
• Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites

  2006cites this paper
• Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice

  2006cites this paper
• Evidence for morphine‐independent central nervous opioid effects after administration of codeine: Contribution of other codeine metabolites

  2006cites this paper
• harmacokinetics and pharmacodynamics f oral oxycodone in healthy human ubjects : Role of circulating active etabolites

  2006cites this paper
• Individualizing analgesic prescription Part I: pharmacogenetics of opioid analgesics.

  2006cites this paper
• Influence of CYP2D6 Genetics on Opioid Kinetics, Metabolism and Response

  2005cites this paper
• Chapter 13 - Applications of genotyping and phenotyping for clinically-relevant polymorphisms of drug metabolizing enzymes and drug transporters

  2004cites this paper
• Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part II.

  2003cites this paper
• Med-psych drug-drug interactions update.

  2002cites this paper